THE COMPANY

Innovate Anti-Infectives is a medical innovations company that licenses re-engineered pharmaceutical platforms in the anti-infectives market.

Innovate Anti-Infectives has entered into an exclusive license for global rights to develop and commercialize Innovate Pharmaceuticals Limited’s proprietary formulation known as Enhanced Liquid Aspirin (“ELA”) in the anti-infectives field.

The Company is conducting clinical trials of ELA to establish whether ELA shows efficacy in the treatment of COVID-19 and pre-clinical trials to establish whether ELA shows efficacy in the treatment of Sepsis.

Outpatient, Liquid Aspirin to Reduce COVID-19 Hospitalizations

Principal Investigator: Frank H. Lau, MD, FACS

  • The current Phase II trial is being conducted in partnership with Louisiana State University represented by Louisiana State University Health Sciences Center – New Orleans by Frank H. Lau, MD, FACS, the trial’s principal investigator

  • The aim of the trial is to obtain reliable and interpretable data that a treatment course of COVID-19 patients with Enhanced Liquid Aspirin can reduce hospitalizations driven by COVID-19-associated coagulopathy (CAC)

  • The study is designed as double-blinded placebo-controlled, randomized trial

LSU is expected to start recruiting 200 patients with early signs of COVID-19 in the next 6 weeks. Newly diagnosed COVID-19 patients will be randomly assigned to either ELA or a placebo for a period of ten days. They will be assessed using a variety of biomarkers and the hope is that those taking ELA will show a reduction in illness severity and duration and therefore will not require hospitalisation.

ENHANCED LIQUID ASPIRIN

Innovate Anti-Infectives has entered into an exclusive license for global rights to develop and commercialize Innovate Pharmaceuticals Limited’s proprietary formulation known as Enhanced Liquid Aspirin (“ELA”) in the anti-infectives field.

What is Enhanced Liquid Aspirin?

  • The only shelf-stable liquid preparation of aspirin

  • In vitro and preclinical data suggest that compared with conventional Aspirin it exhibits enhanced anti-inflammatory activity, equivalent anti-platelet activity, and reduced gastrointestinal intolerance

  • A new patented formulation of Aspirin that we believe utilizes a naturally occurring nanoparticle

  • These tiny particles allow the drug to penetrate the cells of our body much more effectively

  • Unlike standard Aspirin, ELA is small enough to pass through the Blood Brain Barrier

  • It therefore enters brain and other cells it would seem in larger amounts